Addressing the unmet need for a detailed guide to preclinical toxicology research, the book guides scientists through the critically important and rapidly evolving process of answering the question: is a drug safe for patients?
San Antonio, TX (PRWEB) March 11, 2013
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and MPI Research, the largest single-site preclinical contract research organization worldwide, today announced the launch of A Comprehensive Guide to Toxicology in Preclinical Drug Development, a new reference work edited by Dr. Ali Said Faqi, Senior Director of Developmental and Reproductive Toxicology at MPI Research. The book will be featured at the Society of Toxicology’s ToxExpo, March 10-14, 2013.
Addressing the unmet need for a detailed guide to preclinical toxicology research, the book guides scientists through the critically important and rapidly evolving process of answering the question: is a drug safe for patients? A Comprehensive Guide to Toxicology in Preclinical Drug Development is unique because it combines preclinical development for both small and large molecules and covers emerging technology and methods. For the first time, a reference brings this material together with information on vaccines, worldwide regulatory considerations (including Chinese regulations), and other emerging areas to help scientists understand and predict toxicity.
The book will benefit students as they begin work in preclinical environments in either private industry or academia. It also provides practicing toxicologists, new clinicians and regulatory professionals with a comprehensive reference manual on the practical aspects of preclinical work.
A Comprehensive Guide to Toxicology in Preclinical Drug Development, with contributions from 79 leading scientists, covers the latest in vitro, in vivo and technological advances in use today, from investigative toxicology to the evaluation of toxicity and pharmacologic effects of a new chemical entity. Chapter highlights include absorption, distribution, metabolism, excretion (ADME), acute sub-chronic and chronic toxicity testing, toxicogenomics, developmental and reproductive toxicology, carcinogenicity testing, histopathology, imaging, immunotoxicity, and other relevant topics.
# # #
Note to editors:
Full details of the book: A Comprehensive Guide to Toxicology in Preclinical Drug Development by Ali S. Faqi, ISBN: 9780123878151, Academic Press
Copies of the book are available to credentialed journalists upon request; contact Michelle McMahon at +1 781 663-2268 or firstname.lastname@example.org to request a review copy or to schedule an interview with the author.
About the Editor
Ali Said Faqi, DVM, PhD, DABT, Fellow, ATS, is the Senior Director of Developmental and Reproductive Toxicology and a Senior Principal Scientist at MPI Research. He is also an Adjunct Associate Professor at Wayne State University, School of Medicine. Before joining MPI Research, Dr. Faqi was a Senior Scientist at Allergan Pharmaceuticals and Research Toxicologist at IIT Research Institute. He received his PhD from the University of Leipzig in Germany, DVM from Somali National University, and earned a diploma of specialization in Experimental Pharmacology from the University of Milan. He was a postdoctoral Fellow at the Institute of Clinical Pharmacology and Toxicology at the Free University of Berlin-Germany, a Diplomate of American Board of Toxicology (DABT) and a Fellow of the Academy Toxicological Sciences (ATS). Dr. Faqi is a member of the Editorial Boards of Reproductive Toxicology and ISRN Toxicology. He is also a member of the Scientific Advisory Board of the Alzheimer's Art Quilt Initiative (AAQI). Dr. Faqi previously served on the Board of Scientific Counselors (BOSC) Computational Toxicology at the United States Environmental Protection Agency. He is an ad hoc scientific reviewer for several scientific journals, published extensively in the field of developmental and reproductive toxicology, and has won multiple publishing awards.
About MPI Research
MPI Research, with global headquarters in Michigan, provides discovery, safety evaluation, and bioanalytical and analytical testing services (formulation development, regulated bioanalysis, immunochemistry, metals analysis, and environmental analysis) to the biopharmaceutical, medical device, animal health, agricultural, environmental, and chemical industries. Scientific knowledge and experience, quick turnaround, and dedication to strong and enduring Sponsor relationships characterize MPI Research as a high-performance, high-quality organization committed to bringing safer and more effective products to the world. Learn more about how we can go beyond your expectations at http://www.mpiresearch.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).